Johnson & Johnson

JNJ

Market cap $510B

A notable bank and a major investment management firm bought more shares of Johnson & Johnson. The healthcare giant has performed well this year despite some significant headwinds.

Johnson & Johnson has surged 14% since my last update, surpassing my $188 target, and now trades near $200. Top-line growth is accelerating, but revenue expansion remains below industry rates and is partially priced in after a strong rally. JNJ's capital structure remains leveraged, clouding its outlook despite progress in positioning for future success.

In the most recent trading session, Johnson & Johnson (JNJ) closed at $210.01, indicating a +1.68% shift from the previous trading day.

For investors approaching or in retirement, the right stock portfolio balances reliable income, low volatility, and consistent dividend growth.

JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.

The US Equity Income Fund underperformed its benchmark, the Russell 1000 Value Index, net of fees during the third quarter. Enterprise software company, Oracle Corporation, was a top contributor to relative returns during the quarter. Our position in consumer healthcare company, Kenvue Inc., was a top detractor from relative performance during the month.

With the Federal Reserve set to announce its final policy decision of 2025 on Wednesday, investors are rotating into defensive positions. More than the rate-cut possibility (which is around 90% as per recent estimates), the traders are worried about whether the central bank will signal more easing ahead or take a harder stance.

Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.

Investors love S&P 500 dividend stocks, especially those with dependable, high yields, because they provide a substantial passive income stream and offer significant total return potential.

TECVAYLI® and DARZALEX FASPRO® combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up Combination regimen granted Breakthrough Therapy Designation by U.S. FDA ORLANDO, Fla., Dec. 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM).